Cardiovascular drug developer Sanifit raised $82.1m including $62.8m from investors that included existing backer Lundbeckfonden Ventures to bring its overall financing to $149m.

Spain-based vascular calcification medicine developer Sanifit closed a €55.2m ($62.8m) series D round on Wednesday featuring Lundbeckfonden Ventures, the corporate venturing arm of pharmaceutical firm Lundbeck. The round was led by Caixa Capital Risc, the venture capital vehicle for financial services firm La Caixa, and also featured Columbus Venture Partners, Alta Life Sciences, Ysios Capital,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.